Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial by Amel Karaa, Enrico Bertini, Valerio Carelli, Bruce Cohen, Gregory M. Ennes, Marni J. Falk, Amy Goldstein, Gráinne Gorman, Richard Haas, Michio Hirano, Thomas Klopstock, Mary Kay Koenig, Cornelia Kornblum, Costanza Lamperti, Anna Lehman, Nicola Longo, Maria Judit Molnar, Sumit Parikh, Han Phan, Robert D. S. Pitceathly, Russekk Saneto, Fernando Scaglia, Serenella Servidei, Mark Tarnopolsky, Antonio Toscano, Johan L. K. Van Hove, John Vissing, Jerry Vockley, Jeffrey S. Finman, Anthony Abbruscato, David A. Brown, Alana Sullivan, James A. Shiffer, Michelango Mancuso, on behalf of the MMPOWER-3 Trial Investigators

Get full text

ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preserva... by Justis P. Ehlers, MD, Allen Hu, MD, David Boyer, MD, Scott W. Cousins, MD, Nadia K. Waheed, MD, Philip J. Rosenfeld, MD, PhD, David Brown, MD, Peter K. Kaiser, MD, Anthony Abbruscato, PharmD, Gui Gao, PhD, Jeffrey Heier, MD, Prema Abraham, Christopher Devine, Anita Schadlu, George Novalis, Derek Y. Kunimoto, John Parchue, Suk Jin Moon, Zachary Segal, Dennis Marcus, Paul Hahn, Eric Suan, Michael Lee, Victor Gonzalez, Michael A. Samuel, Sunil Patel, Patrick Williams, Brian B. Berger, Henry Kwong, Dante Pieramici, Eric W. Schneider, Yevgeniy Shildkrot, Mathew T. Witmer, Nathan Steinle, Carmelina Gordon, Daniel Learned, Patrick Higgins, Guruprasad Pattar, Vijay Khetpal, Robin Ross, Mark R. Barakat, Sun Young Lee Sjatkowski, David Lally, Troy Becker

Get full text